Daiwa Securities Group Inc. Buys 12,209 Shares of Boston Scientific Co. (NYSE:BSX)

Daiwa Securities Group Inc. increased its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 6.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 209,542 shares of the medical equipment provider's stock after purchasing an additional 12,209 shares during the period. Daiwa Securities Group Inc.'s holdings in Boston Scientific were worth $18,716,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Moran Wealth Management LLC raised its holdings in Boston Scientific by 0.3% in the 4th quarter. Moran Wealth Management LLC now owns 199,624 shares of the medical equipment provider's stock valued at $17,830,000 after acquiring an additional 623 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Boston Scientific by 1.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,292,426 shares of the medical equipment provider's stock valued at $115,439,000 after acquiring an additional 20,726 shares during the last quarter. Enterprise Financial Services Corp acquired a new position in Boston Scientific in the 4th quarter valued at $200,000. Sowell Financial Services LLC increased its holdings in shares of Boston Scientific by 9.1% during the 4th quarter. Sowell Financial Services LLC now owns 20,132 shares of the medical equipment provider's stock worth $1,798,000 after buying an additional 1,675 shares during the last quarter. Finally, AlphaQuest LLC increased its holdings in shares of Boston Scientific by 57.2% during the 4th quarter. AlphaQuest LLC now owns 27,958 shares of the medical equipment provider's stock worth $2,497,000 after buying an additional 10,172 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. Morgan Stanley upped their price objective on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Argus set a $130.00 target price on shares of Boston Scientific in a research note on Tuesday, February 18th. UBS Group upped their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Canaccord Genuity Group increased their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. Finally, Wells Fargo & Company raised their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and an average target price of $108.91.

Boston Scientific Price Performance

Shares of NYSE BSX traded up $0.87 during trading on Wednesday, reaching $96.39. The company had a trading volume of 4,154,110 shares, compared to its average volume of 5,758,404. Boston Scientific Co. has a 52 week low of $65.52 and a 52 week high of $107.17. The stock has a market cap of $142.24 billion, a PE ratio of 77.13, a PEG ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The business's 50 day moving average price is $100.66 and its 200-day moving average price is $91.49.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 1,201 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the transaction, the executive vice president now owns 25,443 shares of the company's stock, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock valued at $14,319,269 over the last quarter. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.